AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
202.57
-2.23 (-1.09%)
Apr 20, 2026, 10:56 AM EDT - Market open
AstraZeneca Revenue
In the year 2025, AstraZeneca had annual revenue of $58.74B with 8.63% growth. AstraZeneca had revenue of $15.50B in the quarter ending December 31, 2025, with 4.11% growth.
Revenue (ttm)
$58.74B
Revenue Growth
+8.63%
P/S Ratio
5.41
Revenue / Employee
$617,655
Employees
95,100
Market Cap
317.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58.74B | 4.67B | 8.63% |
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Eli Lilly and Company | 65.18B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
AZN News
- 3 hours ago - Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD - Business Wire
- 8 hours ago - AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups - Reuters
- 3 days ago - AstraZeneca (AZN) Sees Leadership Changes in CDC Announced by President Trump - GuruFocus
- 4 days ago - AstraZeneca (AZN) Advances Portfolio with Strategic Update - GuruFocus
- 5 days ago - Only Two Days Away – Don't Miss it! C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy's 2026 New York Summit. Be a Part of It. Register Now. - Benzinga
- 6 days ago - Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative 'personalized off-the-shelf' immunotherapy toward clinical development - Benzinga
- 9 days ago - Trump policies, China's biotech boom are ending Europe's pharma powerhouse era - CNBC
- 9 days ago - Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - GuruFocus